Oppenheimer analyst Jay Olson maintained a Hold rating on Editas Medicine (EDIT – Research Report) today and set a price target of ...

In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Editas Medicine (EDIT – Research Report). The ...

Editas stock falls on a decision to seek a partner for its lead gene-therapy candidate, reni-cell, for SCD and TDT and focus ...

The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.

AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...

Editas Medicine Inc. has achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell (HSPC) ...

Editas Medicine (Nasdaq: EDIT) has announced plans to seek a partner or buyer for its lead CRISPR program, reni-cel, as the ...

Achieved in vivo preclinical proof of concept of hematopoietic stem and progenitor cell editing by utilizing Editas ...

The gene editing company will focus on “in vivo” medicines, while seeking to license out or find a development partner for ...

Editas is partnering its CRISPR platform with Genevant’s LNP technology to develop novel gene editing medicines in a deal ...

Editas Medicine, Inc. ( NASDAQ: EDIT) Strategic Update Conference Call October 22, 2024 8:00 AM ET ...

Editas Medicine is ousting its ex vivo sickle cell and beta thalassemia gene therapy to instead focus on an in vivo treatment ...